FOSTER CITY, Calif.--(BUSINESS WIRE)--Notable Labs, Inc. (Notable), a clinical-stage platform therapeutics company designing and delivering predictive precision medicines, today announced the appointment of Chris Whitmore as Chief Financial Officer. In this role, Mr. Whitmore will be a key member of the executive leadership team and will lead Notable’s financial strategy, planning and operations.
“We are delighted to welcome Chris to the Notable management team, where he brings two decades of financial, operational and strategic leadership experience,” said Thomas Bock, M.D., Chief Executive Officer of Notable. “Chris’ successful track record within private and public life sciences companies will be valuable as we continue to expand Notable’s therapeutic pipeline and demonstrate the power and benefit of our predictive precision medicines platform.”
Mr. Whitmore joins Notable from Harpoon Therapeutics where he successfully supported over $250 million in fundraising, including the company’s crossover round and IPO, and served as VP Finance and Administration as well as Corporate Secretary. Prior to Harpoon Therapeutics, Mr. Whitmore served in management positions at Immune Design, AcelRx Pharmaceuticals and Sangamo Therapeutics. Mr. Whitmore began his career at KPMG, where he served as a manager in the audit practice. Mr. Whitmore graduated from the University of California, Santa Barbara, B.A. Business Economics with highest honors, and is a licensed CPA.
About Notable
Notable is a clinical-stage platform therapeutics company designing and delivering predictive precision medicines, a new class of medicines. Notable aims to be the leader in predictive precision medicine and revolutionize the way in which patients seek and receive treatments that work best for them – patient by patient, and cancer by cancer. By transforming historical standards of care, Notable expects to provide dramatic impact for patients and the healthcare community.
Notable’s proprietary predictive precision medicines platform bio-simulates a patient’s cancer treatment and predicts whether a patient will respond to a specific cancer treatment. Using its high-fidelity platform, Notable can identify and select clinically responsive patients prior to their treatment and fast-track clinical development in this patient population. Notable has created a targeted, triple de-risked in-licensing strategy to deliver a product’s medical impact and commercial value faster, higher, and more likely than traditional drug development.
Investors in Notable include B Capital Group, Lifeforce Capital, Builders VC, Founders Fund, Lightspeed Venture Partners, Y Combinator, First Round Capital as well as 11.2 Capital, Refactor Capital, Upside Partnership, and Fuel Ventures.
Notable is headquartered in Foster City, California. Learn more at www.notablelabs.com and follow us @notablelabs.
